What Should Life Sciences Startups Know About Reimbursement?

Reimbursement for Life Sciences Startups - JR Assocates VP Global Health Policy Jo Ellen Surzberg at Harvard Innovation Lab

Perspectives on Medical Reimbursement By JR Associates “Will my device be reimbursed?” This is one of the most important questions life sciences entrepreneurs must consider when developing new medical technology. But in today’s dynamic and complex healthcare environment, clear answers can be elusive. Harvard Innovation Lab recently invited our VP of Global Health Policy, Jo Ellen Slurzberg, to help clarify…

Read More »

Autism Investment Conference Session Notes

Jo Ellen Slurzberg_Reimbursement Strategies Autism Investment Conference

Perspectives on Medical Reimbursement By JR Associates Continuing its efforts to cultivate a marketplace of innovation that better serves those affected by autism, Autism Speaks recently hosted its third annual Autism Investment Conference in Boston. Our VP of Global Health Policy, Jo Ellen Slurzberg, was among the nearly 200 investors, entrepreneurs, healthcare advocates and corporate…

Read More »

Reimbursement Strategy: Extending Product Reach Across Multiple Markets

How medical technology innovators can leverage reimbursement strategy across markets

Perspectives on Medical Reimbursement By JR Associates When medical technology companies develop reimbursement strategies for the U.S. market, it’s a smart business move to look beyond this country’s borders. That’s the advice JR Associates VP of Global Health Policy, Jo Ellen Slurzberg shared in a recent interview with Medical Device Daily. Jo Ellen acknowledged that planning…

Read More »

Bundled Payments: Implications for Medical Device & Drug/Biologic Companies

Bundled Payments for Medical Technology

Perspectives on Medical Reimbursement By JR Associates Recently, the trade press and mainstream news have been paying a lot of attention to bundled payments. Stories have focused primarily on how this shift in medical reimbursement will affect patients, providers and payers. Payers and provider networks are creating internal systems to identify the cost of treating…

Read More »

Medical Device Innovation: Is a Code Necessary for Commercial Adoption?

Perspectives on Medical Reimbursement By JR Associates For some medical devices, more than one reimbursement pathway may be viable. And, as JR Associates recently explained to Medical Device Daily, that could be the case for the Dune MarginProbe – a system that delivers real-time breast cancer detection in the operating room, by helping surgeons assess…

Read More »

Coding For Hypothermia; Clarifying New Standards

Perspectives on Medical Reimbursement By JR Associates Reprinted from The Society of Critical Care Medicine Contributing Authors: Kim Norton* Managing Partner, Argenta Advisors Seattle, Washington, USA Judy Rosenbloom** President, JR Associates Reseda, California, USA George A. Sample, MD*** Washington Hospital Center Washington, D.C. In 2005, the American Heart Association published guidelines (Class IIa and IIb)…

Read More »

ASE Chooses Judy Rosenbloom As Reimbursement Consultant

Los Angeles—July 2005—The American Society of Echocardiography (ASE) today announced that JR Associates founder and president, Judy Rosenbloom, has been named Coding and Reimbursement Consultant. On an ongoing basis, Rosenbloom will provide strategic consulting for the ASE membership. A former ASE board member and Advocacy Committee member, Rosenbloom is deeply familiar with ASE’s structure and…

Read More »